Zinzino AB announces acquisition of Sanki to enhance wellness presence throughout Americas

Zinzino AB (publ.), the Swedish direct sales wellness company listed on Nasdaq First North, has signed a definitive agreement to acquire Sanki, a Mexico-based health-focused direct selling business. The transaction includes full ownership of Sanki’s subsidiaries in Colombia and Peru and aims to strengthen Zinzino AB’s distribution network and product portfolio across key markets in North and South America.

The purchase is structured as a combined asset and share deal, valued at USD 8 million. Of this, USD 7 million will be settled through the issuance of new Zinzino AB shares, while the remaining USD 1 million will be paid in cash from the company’s internal reserves. The agreement also includes the potential for an earn-out of up to USD 12 million in additional shares, contingent on future sales performance benchmarks.

Zinzino AB will acquire Sanki’s distributor database, customer records, inventory, and all relevant intellectual property rights. By securing these assets and the full equity of its subsidiaries in Colombia and Peru, Zinzino AB is accelerating its market entry into Latin America while enhancing its global supply chain for wellness products built on cellular-level diagnostics.

What strategic advantages does Zinzino AB gain by acquiring Sanki’s Latin American operations?

Sanki, which operates in the United States, Mexico, Colombia, and Peru, currently generates around USD 12 million in annual revenue. Its portfolio includes patented and trademarked nutraceutical products aimed at metabolic health, cellular vitality, and holistic well-being. These offerings will now be integrated into Zinzino AB’s test-based health product ecosystem, which uses lab diagnostics to personalize supplement regimens for customers.

Zinzino AB Chief Executive Officer Dag Bergheim Pettersen noted that the transaction aligns with the company’s long-term strategy of sustainable and profitable growth through targeted acquisitions and technology-driven wellness solutions. He stated that personalized, data-backed consumer experiences are shaping the future of health and wellness, and that the collaboration with Sanki represents a meaningful step forward in building a scalable, customer-centric platform for the Americas.

The acquisition is expected to close on January 1, 2026.

How does this fit into Zinzino AB’s broader acquisition strategy across the wellness sector?

Zinzino AB has been expanding its global footprint through a series of acquisitions over the past five years. In 2020, the company acquired VMA Life, followed by Enhanzz in 2022. The year 2024 saw the acquisitions of Xelliss and ACN, while 2025 included asset acquisitions of Zurvita, Valentus, Ecosystem, Truvy, and Bode Pro. Each transaction has helped reinforce Zinzino AB’s position as a leader in the direct selling of biotechnology-based health products. The company has built a test-based wellness model anchored in diagnostics, personalization, and a vertically integrated distribution network.

How will Sanki’s patented nutraceuticals be integrated into Zinzino AB’s diagnostic-led platform?

Sanki’s integration will focus on leveraging synergies between its proprietary products and Zinzino AB’s diagnostics-led product architecture. By aligning Sanki’s offerings with Zinzino AB’s test-based framework, the goal is to enhance health outcomes for customers while boosting lifetime value per subscriber. The existing technological infrastructure and organizational scale of Zinzino AB will be used to operationalize the integration rapidly across both Colombia and Peru, markets that are expected to see accelerated penetration as a result.

Sanki’s co-founder and Chief Executive Officer Alejandro Lopez Tello will continue to collaborate closely with Zinzino AB as the two companies combine their expertise to expand product innovation and market outreach. Tello brings decades of experience in the wellness industry, and his continued presence is expected to support brand continuity and local market execution.

What do Zinzino AB’s latest monthly and year-to-date financials reveal about growth momentum?

This acquisition comes amid a surge in revenue for Zinzino AB. In October 2025, sales revenue from its core sales markets rose by 70 percent year-over-year to SEK 324.8 million, up from SEK 191.6 million during the same month last year. Group revenue, including Faun Pharma, totaled SEK 327.5 million for October 2025, marking a 65 percent year-over-year increase.

For the period from January through October 2025, Zinzino AB reported group revenue of SEK 2.63 billion, a 55 percent increase from SEK 1.69 billion during the corresponding period in 2024. The company’s geographic performance highlights the effectiveness of its global expansion strategy, with standout growth in North America and Asia-Pacific.

Which global regions are delivering the highest growth for Zinzino AB in 2025 so far?

In North America, monthly revenue surged 167 percent year-over-year to SEK 51.6 million in October 2025. The Asia-Pacific region, including markets such as India, Singapore, and Australia, reported a 384 percent increase in monthly revenue, reaching SEK 28.1 million. Other regions such as Central Europe and South and West Europe also delivered robust performance, growing 88 percent and 56 percent respectively.

Conversely, Faun Pharma, Zinzino AB’s manufacturing subsidiary, reported a 63 percent decline in external sales for October 2025, falling to SEK 2.7 million from SEK 7.3 million in October 2024. This reduction is seen as a deliberate strategic shift, with Zinzino AB prioritizing high-growth, market-facing business segments over internal production volumes.

How are institutional investors and analysts reacting to Zinzino AB’s M&A-led expansion model?

From an institutional perspective, Zinzino AB’s acquisition of Sanki has been well received. Analysts tracking the Scandinavian health and wellness sector view this deal as part of a calculated M&A strategy that targets underpenetrated yet fast-growing regions. The earn-out component based on future revenue milestones is also being interpreted as a disciplined approach to performance-based integration, providing financial flexibility while aligning incentives for growth.

Zinzino AB’s model of acquiring brand portfolios with strong local roots and embedding them into its global test-based wellness platform has helped reduce customer acquisition costs and improve margins across geographies. The use of share-based consideration for the majority of the transaction preserves capital for further investments in technology and product development. Analysts also noted that the absence of debt financing for this transaction enhances Zinzino AB’s financial stability during a period of rapid expansion.

What is the long-term outlook for Zinzino AB’s personalized wellness strategy in Latin America?

Going forward, the integration of Sanki into Zinzino AB’s operations is expected to create cross-selling opportunities, deepen customer engagement in the Americas, and support the rollout of personalized wellness programs tailored to regional needs. The focus will remain on expanding reach while improving health outcomes through individualized diagnostics and science-backed supplementation.

With Sanki added to its expanding global portfolio, Zinzino AB is positioning itself to not only drive deeper into North and South American markets but also to solidify its leadership in the intersection of biotechnology, direct sales, and personalized health. Analysts expect additional acquisitions in adjacent wellness categories and emerging markets to follow in the next 12 to 18 months, reinforcing Zinzino AB’s long-term global growth roadmap.

What are the key takeaways from Zinzino AB’s acquisition of Sanki and revenue surge in 2025?

• Zinzino AB has acquired Mexico-based Sanki for USD 8 million, with 87.5 percent of the amount paid in newly issued shares and the rest in cash.
• The deal includes full ownership of Sanki’s subsidiaries in Colombia and Peru, accelerating Zinzino AB’s entry into Latin American markets.
• Sanki’s patented wellness products will be integrated into Zinzino AB’s test-based, diagnostics-led nutrition platform.
• October 2025 group revenue rose 65 percent year-over-year to SEK 327.5 million, with core markets showing robust double- and triple-digit growth.
• North America revenue jumped 167 percent, while Asia-Pacific revenue rose 384 percent compared to the same month last year.
• Year-to-date group revenue for January–October 2025 reached SEK 2.63 billion, up 55 percent from 2024.
• Analysts view the Sanki acquisition as a strategic step in Zinzino AB’s long-term M&A-led growth roadmap.
• The transaction structure preserves cash while enabling upside through a performance-linked earn-out of up to USD 12 million in additional shares.
• Future expansion will likely focus on product localization, diagnostics-driven personalization, and increased cross-selling across global markets.